Bryce Point Capital LLC Takes $590,000 Position in Envista Holdings Co. (NYSE:NVST)

Bryce Point Capital LLC purchased a new stake in shares of Envista Holdings Co. (NYSE:NVST - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 30,579 shares of the company's stock, valued at approximately $590,000.

Several other hedge funds and other institutional investors also recently modified their holdings of NVST. Venturi Wealth Management LLC lifted its position in Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after purchasing an additional 1,638 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock worth $44,000 after acquiring an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista during the fourth quarter valued at approximately $53,000. Mitsubishi UFJ Trust & Banking Corp purchased a new stake in shares of Envista in the 4th quarter worth approximately $86,000. Finally, KBC Group NV grew its stake in shares of Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company's stock worth $152,000 after acquiring an additional 3,082 shares during the last quarter.

Envista Stock Performance

NVST stock traded up $0.13 during trading on Tuesday, reaching $15.42. The company had a trading volume of 950,535 shares, compared to its average volume of 2,452,956. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista Holdings Co. has a twelve month low of $14.61 and a twelve month high of $23.00. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -2.37, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. The firm has a 50-day simple moving average of $19.05 and a 200-day simple moving average of $19.50.

Envista (NYSE:NVST - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, sell-side analysts expect that Envista Holdings Co. will post 1 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on NVST shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a report on Thursday, March 6th. Wells Fargo & Company set a $19.00 price target on Envista in a research report on Saturday, March 8th. New Street Research set a $19.00 price target on shares of Envista in a report on Thursday, March 6th. UBS Group lowered their price objective on Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Monday, March 10th. Finally, Morgan Stanley dropped their target price on shares of Envista from $20.00 to $19.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $20.18.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.